Table I.

Profiles of representative TCCs/TCLsa

PhenotypebStimulation IndexCytokine ProfilecBlockingdCytokine Levels (pg/ml) (IFN-γ/IL-2/IL-4/IL-8)
Clones
 I-43CD41/34.02II94890/0/6193/0
 E10E9CD45.17.32II28535/574/8300/615
 F10F5-1CD423.30I250000/5957/32705/71970
 F10F5-2CD413.63.02n.d.e141350/1048/29470/0
 E10C8CD41413.80I/II131740/8933/26075/15801
 I-1CD821.318.2n.d.In.d.
 I-16CD813.18.31I26240/1155/134/0
Lines
 I-8CD46/13.699.02II64560/0/12248/25
 F11E5CD41/222.50II33610/3057/7874/2723
 F11F5CD4/CD813.1/172.9n.d.n.d.n.d.
 I-10CD4/CD85.1/2216.8n.d.n.d.n.d.
 I-12CD4/CD82/5.1/21.33.3n.d.n.d.n.d.
 I-17CD4/CD82/21.311.2n.d.n.d.n.d.
 I-26CD83/?27.61I132540/0/1599/0
 F11D3CD87/174.21I/II55330/0/4478/25
 E10D9CD87/162.61n.d.99285/0/3445/0
  • a Clone/Line names are given.

  • b Monoclonality and oligoclonality were confirmed by FCM using a battery of mAbs against TCRVβ. ?, Indicates unknown Vβ by this analysis. Underlines indicate shared Vβs.

  • c Cytokine production profiles are indicated as 1 for type 1 and 2 for type 2.

  • d Inhibition of T cell proliferation by anti-HLA-A,B,C (class I) and anti-HLA-DQ, DR (class II) Abs is indicated as I and II, respectively. I/II indicates partial inhibition by both types of mAbs.

  • e n.d., not done.